<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02997319</url>
  </required_header>
  <id_info>
    <org_study_id>2016P000651</org_study_id>
    <secondary_id>R01DK105072</secondary_id>
    <nct_id>NCT02997319</nct_id>
  </id_info>
  <brief_title>Shift Work, Heredity, Insulin, and Food Timing Study</brief_title>
  <acronym>SHIFT</acronym>
  <official_title>Shift Work, Heredity, Insulin, and Food Timing (SHIFT) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Broad Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether night time eating that coincides with&#xD;
      elevated endogenous melatonin impairs glucose tolerance, particularly in carriers of the&#xD;
      MTNR1B risk allele.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary observations suggest that food intake coincident with high melatonin levels leads&#xD;
      to impaired glucose tolerance-particularly in MTNR1B risk allele carriers. Our objectives are&#xD;
      to determine the effect of concurrent food intake and melatonin on glucose tolerance; and to&#xD;
      assess the role of MTNR1B single nucleotide polymorphism (SNP)*melatonin interaction in this&#xD;
      deleterious effect. Our central hypothesis is that concurrent high melatonin levels and food&#xD;
      intake, commonly experienced in night shift workers, cause long-term impairment of glucose&#xD;
      tolerance and that this effect is worse in carriers of the MTNR1B type 2 diabetes (T2D) risk&#xD;
      SNP than in non-carriers. The results of this proposal will help to clarify an ongoing&#xD;
      controversy about the role of melatonin in glucose tolerance, and will help to develop novel&#xD;
      strategies in the prevention and treatment of T2D, especially in shift workers, night eaters,&#xD;
      and MTNR1B risk allele carriers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Actual">May 8, 2021</completion_date>
  <primary_completion_date type="Actual">May 8, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) glucose</measure>
    <time_frame>Between 0-120 minutes, Visit 2 and 3</time_frame>
    <description>Investigators will measure insulin and glucose levels for 120 minutes at day time and night time visits, and compare them by genotype at selected loci.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disposition index</measure>
    <time_frame>Between 0-120 minutes, Visit 2 and 3</time_frame>
    <description>Disposition index will be determined by frequently sampled oral glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corrected Insulin Response</measure>
    <time_frame>Between 0-120 minutes, Visit 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity Index</measure>
    <time_frame>Between 0-120 minutes, Visit 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose</measure>
    <time_frame>Between 0-120 minutes, Visit 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin</measure>
    <time_frame>Between 0-120 minutes, Visit 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Melatonin</measure>
    <time_frame>Between 0-120 minutes, Visit 2 and 3</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Sleep Duration</measure>
    <time_frame>Total of 2 weeks between Visit 1 and 3</time_frame>
    <description>Sleep duration will be computed from self-reported bed and wake up times using sleep logs and measured using an Actiwatch.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>Total of 2 weeks between Visit 1 and 3</time_frame>
    <description>Sleep quality will be assessed using the Pittsburgh Sleep Quality Index and Insomnia Severity Index</description>
  </other_outcome>
  <other_outcome>
    <measure>Light Exposure</measure>
    <time_frame>Total of 2 weeks between Visit 1 and 3</time_frame>
    <description>Measured using Actiwatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Energy Intake</measure>
    <time_frame>Total of 2 weeks between Visit 1 and 3</time_frame>
    <description>Total energy intake in kcal/day will be computed from 14-day 24-hr dietary recalls</description>
  </other_outcome>
  <other_outcome>
    <measure>Dietary Composition</measure>
    <time_frame>Total of 2 weeks between Visit 1 and 3</time_frame>
    <description>Macronutrient and micronutrient intake will be computed from 14-days of self-reported 24-hr dietary recalls</description>
  </other_outcome>
  <other_outcome>
    <measure>Dietary Intake Timing</measure>
    <time_frame>Total of 2 weeks between Visit 1 and 3</time_frame>
    <description>Food timing will be self-reported and averaged across 14-days of 24-hr dietary recalls</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical Activity</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessed using the International Physical Activity Questionnaire (IPAQ)</description>
  </other_outcome>
  <other_outcome>
    <measure>Chronotype</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessed using the Morningness-Eveningness Questionnaire (MEQ)</description>
  </other_outcome>
  <other_outcome>
    <measure>Emotional Eating Behavior</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessed using the Emotional Eating Questionnaire (EEQ)</description>
  </other_outcome>
  <other_outcome>
    <measure>Depression</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessed using the Patient Health Questionnaire (PHQ-8)</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">365</enrollment>
  <condition>Shift Work Type Circadian Rhythm Sleep Disorder</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Circadian Rhythm Sleep Disorder, Shift Work Type</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Night Shift-Workers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Day Workers</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA, serum insulin, serum glucose, plasma melatonin, blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects residing in New England (USA) region&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant female&#xD;
&#xD;
          -  18-60 years&#xD;
&#xD;
          -  Currently employed (night shift workers and day workers), graduate students, part-time&#xD;
             workers, or unemployed&#xD;
&#xD;
          -  Able and willing to give consent relevant to genetic investigation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently taking any medications for the treatment of diabetes&#xD;
&#xD;
          -  Currently taking medications known to affect glycemic parameters, such as&#xD;
             glucocorticoids, growth hormone or fluoroquinolones&#xD;
&#xD;
          -  Pregnant, nursing or at risk of becoming pregnant&#xD;
&#xD;
          -  Chronic renal failure, hepatic diseases, or cancer diagnoses&#xD;
&#xD;
          -  Bulimia diagnosis, prone to binge eating&#xD;
&#xD;
          -  Eating disorder diagnosis such as anorexia, binge eating, or bulimia&#xD;
&#xD;
          -  With psychiatric illness, such as schizophrenia or bipolar affective disorder&#xD;
&#xD;
          -  Blind&#xD;
&#xD;
          -  History of bariatric surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richa Saxena, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank AJL Scheer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.partners.org/study/shiftstudy</url>
    <description>Recruitment Website</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Richa Saxena</investigator_full_name>
    <investigator_title>Assistant Professor of Anaesthesia</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Shift Work</keyword>
  <keyword>Circadian Rhythms</keyword>
  <keyword>MTNR1B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Sleep Disorders, Circadian Rhythm</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

